Clinical trials: Rectal Cancer Patients
Colorectal Cancer
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
Regorafenib in third-line treatment of metastatic colorectal cancer(mCRC) significantly prolongs the survival of patients, and its advancement has a sensitizing effect on postline chemotherapy and thus improves the prognosis of…
- Trial name
- NCT05818267
- Testing
- Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wei Zhang
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
- Trial name
- RECOURSE (NCT01607957)
- Testing
- TAS-102
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 800 people
- Sponsor
- Taiho Oncology, Inc.
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Colorectal Neoplasms Malignant
Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been identified as the cause of the Coronavirus disease 19 (COVID-19), which was initially reported in December 2019 in China and has since rapidly spread…
- Trial name
- COVID-CRC (NCT04712292)
- Testing
- Surgical procedure for confirmed or suspected colorectal cancer
- Where
- 45 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Bologna
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005036
- Testing
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
AI-Assisted Chemotherapy Side Effect Management
This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors.
- Trial name
- ALLIANCE (NCT07198581)
- Testing
- LLM-assisted chemotherapy side effect management
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Incheon St.Mary's Hospital
Anal Cancer Squamous Cell
Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)
Phase II randomized study of the use of pre-and probiotics during the definitive treatment of chemotherapy-radiotherapy (Ch-RT) for patients with localized anal canal squamous cell cancer (ACSCC) with the objective of increasing…
- Trial name
- BISQUIT (NCT03870607)
- Testing
- prebiotics in combination with probiotics
- Where
- Brazil
- Volunteers
- 75 people
- Sponsor
- AC Camargo Cancer Center
Fasting
Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients
This study will evaluate the ability of short-term fasting to reduce chemotherapy toxicity and enhance anti-tumour response in patients with colorectal carcinoma subjected to chemotherapy.
- Trial name
- CHEMOFAST (NCT04247464)
- Testing
- Fasting
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- IMDEA Food
Colorectal Neoplasms
Diagnostic Performance Assessment of Qualitative Ifobt and Quantitative Ifobt for Advanced Neoplastic
In Argentina, there is vast experience in qualitative iFOBT population screening that is part of the CRC Prevention and Early Detection National Program. The screening's cut-off point is at 50 ng/mL buffer.
- Trial name
- NCT04831632
- Testing
- quantitative and qualitative iFOBTs
- Where
- Argentina
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- CECILIA CURVALE
Rectal Cancer
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
Irinotecan is one of effective drugs for colorectal cancer. In neoadjuvant chemoradiotherapy (CRT), Irinotecan is prescribed in a low dose of 50mg/m2/week because of toxicity.
- Trial name
- NCT01474187
- Testing
- Irinotecan, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Colorectal Cancer, Type 2 Diabetes
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
The goal of this observation study is to deliver an education program designed to increase knowledge of colorectal cancer prevention and nutrition education in minorities with Type 2 diabetes.
- Trial name
- NCT05765214
- Testing
- Intervention Group (IG)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers.
- Conditions
- Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03602885
- Testing
- Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Resected Colon Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells.
- Trial name
- NCT00378716
- Testing
- 5-fluorouracil, leucovorin calcium, tegafur
- Volunteers
- 1,608 people
- Sponsor
- NSABP Foundation Inc
Rectal Adenocarcinoma, Circulating Tumor DNA
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the…
- Conditions
- Rectal Adenocarcinoma, Circulating Tumor DNA, Minimal Residual Disease, Neoadjuvant Chemoradiotherapy
- Trial name
- NCT05969938
- Testing
- MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- WeiWei Xiao
Colorectal Cancer, Liver Metastases
Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis
Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for patients with primarily unresectable colorectal liver metastasis
- Trial name
- NCT04912258
- Testing
- Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Colo-rectal Cancer, Neuropathy;Peripheral
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
This study aims to: Evaluate the possible protective effect of pentoxifylline against oxaliplatin induced peripheral neuropathy and chemotherapy induced mucositis in patients with stage II and stage III colorectal cancer.
- Conditions
- Colo-rectal Cancer, Neuropathy;Peripheral, Mucositis
- Trial name
- NCT05590117
- Testing
- Pentoxifylline, FOLFOX-6 regimen
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Tanta University
Metastatic Colorectal Cancer
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
This study aims to evaluate the safety and efficacy of Immuncell-LC, the adoptive immuntherapeutic agent composed of a CIK cell agent, to treat patients with metastatic colorectal cancer, which are refractory to the 3rd-line…
- Trial name
- NCT03220984
- Testing
- Immuncell-LC intravenous infusion using a CIK cell agent
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Gangnam Severance Hospital
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.